Literature DB >> 10504047

Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography.

B Misselwitz1, J Platzek, B Radüchel, J J Oellinger, H J Weinmann.   

Abstract

RATIONALE AND
OBJECTIVES: Differential diagnosis of malignant and beign lymph nodes is still a problem in lymphographic imaging modalities. Plain magnetic resonance imaging (MRI) and computed tomography (CT) are inadequate for detecting metastases in normal-sized lymph nodes and for differentiating enlarged nodes. Therefore it is important to have a contrast agent that accumulates in healthy lymphatic tissue but does not accumulate in metastatic deposits.
METHODS: The lymphographic contrast agent Gadofluorine 8 (Schering AG, Berlin, Germany) is a lipophilic but water-soluble gadolinium complex. Lymphographic effects were investigated in guinea pigs, dogs, and tumor-bearing rabbits after interstitial (subcutaneous or intracutaneous) injection. MR imaging was performed using T1-weighted gradient-echo sequences until 120 min after administration.
RESULTS: After interstitial injection Gadofluorine 8 accumulates in regional lymph nodes, resulting in a pronounced increase in signal intensity in the lymph nodes. Differentiation between normal and metastatic lymph nodes was achieved.
CONCLUSIONS: Gadofluorine 8 is an innovative contrast agent that can distinguish between normal and tumorous lymph nodes in interstitial MR lymphography.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504047     DOI: 10.1007/BF02594598

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  17 in total

Review 1.  Contrast-enhanced lymphography. CT or MR imaging?

Authors:  T J Vogl; M Bartjes; K Marzec
Journal:  Acta Radiol Suppl       Date:  1997

2.  Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes.

Authors:  A Mühler; X Zhang; H Wang; R Lawaczeck; H J Weinmann
Journal:  Invest Radiol       Date:  1995-02       Impact factor: 6.016

3.  Characterization of reactive versus tumor-bearing lymph nodes with interstitial magnetic resonance lymphography in an animal model.

Authors:  P Vassallo; C Matei; W D Heston; S J McLachlan; J A Koutcher; R A Castellino
Journal:  Invest Radiol       Date:  1995-12       Impact factor: 6.016

4.  Experimental lymph node metastases: enhanced detection with MR lymphography.

Authors:  R Weissleder; G Elizondo; L Josephson; C C Compton; C J Fretz; D D Stark; J T Ferrucci
Journal:  Radiology       Date:  1989-06       Impact factor: 11.105

5.  Lymphatic imaging.

Authors:  C L Witte; W H Williams; M H Witte
Journal:  Lymphology       Date:  1993-09       Impact factor: 1.286

6.  Iotasul, a water-soluble contrast agent for direct and indirect lymphography. Results of preclinical investigations.

Authors:  H M Siefert; W Mützel; C Schöbel; H J Weinmann; B I Wenzel-Hora; U Speck
Journal:  Lymphology       Date:  1980-09       Impact factor: 1.286

7.  MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM.

Authors:  L Harika; R Weissleder; K Poss; C Zimmer; M I Papisov; T J Brady
Journal:  Magn Reson Med       Date:  1995-01       Impact factor: 4.668

8.  Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies.

Authors:  L Harika; R Weissleder; K Poss; M I Papisov
Journal:  Radiology       Date:  1996-02       Impact factor: 11.105

9.  Indirect computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model.

Authors:  E R Wisner; R W Katzberg; D P Link; S M Griffey; C M Drake; A R Vessey; D Johnson; P J Haley
Journal:  Acad Radiol       Date:  1996-01       Impact factor: 3.173

10.  MR lymphography: study of a high-efficiency lymphotrophic agent.

Authors:  R Weissleder; J F Heautot; B K Schaffer; N Nossiff; M I Papisov; A Bogdanov; T J Brady
Journal:  Radiology       Date:  1994-04       Impact factor: 11.105

View more
  8 in total

1.  MR imaging-guided axillary node biopsy for breast cancer: initial findings.

Authors:  Takuji Yamagami; Sachiko Yuen; Kiyoshi Sawai; Tsunehiko Nishimura
Journal:  Eur Radiol       Date:  2003-06-14       Impact factor: 5.315

2.  Indirect magnetic resonance lymphography of the head and neck of dogs using Gadofluorine M and a conventional gadolinium contrast agent: a pilot study.

Authors:  Monique N Mayer; Susan L Kraft; Daniel S Bucy; Cheryl L Waldner; Kirsten M Elliot; Sheldon Wiebe
Journal:  Can Vet J       Date:  2012-10       Impact factor: 1.008

3.  Dextran gadolinium complexes as contrast agents for magnetic resonance imaging to sentinel lymph nodes.

Authors:  Guo-Ping Yan; Wei Xu; Lian Yang; Liang Li; Fan Liu; Qing-Zhong Guo
Journal:  Pharm Res       Date:  2010-06-18       Impact factor: 4.200

Review 4.  Contrast-enhanced MR imaging of lymph nodes in cancer patients.

Authors:  Seung Hong Choi; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

5.  Magnetic resonance labeling of stem cells: is positive tracking a plus or a minus?

Authors:  Dara L Kraitchman; Peter Caravan
Journal:  JACC Cardiovasc Imaging       Date:  2009-09

6.  Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability.

Authors:  Marc Sirol; Pedro R Moreno; K-Raman Purushothaman; Esad Vucic; Vardan Amirbekian; Hanns-Joachim Weinmann; Paul Muntner; Valentin Fuster; Zahi A Fayad
Journal:  Circ Cardiovasc Imaging       Date:  2009-08-17       Impact factor: 7.792

7.  Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent.

Authors:  B Misselwitz; H Schmitt-Willich; W Ebert; T Frenzel; H J Weinmann
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

8.  Quantitative and qualitative estimation of atherosclerotic plaque burden in vivo at 7T MRI using Gadospin F in comparison to en face preparation evaluated in ApoE KO mice.

Authors:  Caroline Jung; Sabine Christiansen; Michael Gerhard Kaul; Eva Koziolek; Rudolph Reimer; Jörg Heeren; Gerhard Adam; Markus Heine; Harald Ittrich
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.